iShares Genomics Immunology and Healthcare ETF

iShares Genomics Immunology and Healthcare ETF (IDNA) is a BlackRock index fund that tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. The index holds about 50 drugmakers and healthcare companies worldwide, chosen by their business ties to genomics and immunology. Its global reach sets it apart from US-focused biotech funds, with about 40% of assets outside the US as of July 31, 2026. It costs 0.47% a year and swings sharply: it lost 42% in 2022.

• Over the year to Oct 27, 2026, IDNA returned +66.9%, 1st of 7 among similar funds.
• Its 5-year annualized return was -2.1%.
• In the 2020 COVID crash it fell 26.9% and regained its old high 1.1 months after the low.
• Its worst full calendar year was 2022 (-42.3%); its best was 2020 (+54.3%).
• The deepest fall in its price history was 68.3% (Sep 2, 2021 to Oct 27, 2023), not yet recovered.

As of Jul 31, 2026, the fund held 58 securities; the ten largest made up 42.99% of assets, and 10.49% sat in cash and money-market holdings.

• Over the three months to Jul 31, 2026, investors added a net $14.8M (creations minus redemptions, per the N-PORT report).
• Monthly total returns reported for that quarter: +1.66%, +12.93%, -3.90%.

IDNA follows an index run by ICE Data Indices. The index starts with companies listed in 42 developed and emerging market countries that earn at least half their revenue from biopharmaceutical, healthcare equipment or healthcare services businesses, as defined by FactSet's industry classification system. ICE then searches FactSet's supply chain database for keywords tied to genomics and immunology products. It scores each company by how many of those links it has, and the 50 highest scorers make the index.

Holdings are weighted by float-adjusted market value. That means bigger companies get bigger weights, counting only shares the public can trade. No single company can exceed 4% at a rebalance, and the diversified biopharmaceutical group is capped at 25%. The index rebuilds its list each December and resets weights twice a year, so positions can drift above the cap in between. As of July 31, 2026, Bayer and Twist Bioscience were each about 4.8% of the fund.

BlackRock uses representative sampling. This means it holds a group of stocks expected to behave like the index, which may not be every index member. At least 80% of assets go into index stocks or close equivalents such as depositary receipts. Up to 20% can go into futures, options, swaps, cash and other securities. The fund may lend out up to one-third of its assets. Portfolio turnover was 49%, according to the prospectus filed November 21, 2025.

• IDNA charges 0.47% a year, versus an average of 0.48% for the similar funds below (5th of 7, cheapest first).
• Using the prospectus's standard example, $10,000 invested would cost about $48 in the first year and $591 over 10 years (assuming a 5% annual return).

IDNA is a narrow, volatile theme fund with a small yield, so it fits as a small add-on rather than a foundation.

IDNA adds focused exposure to genomics and immunology drugmakers in the US, Europe and Japan. Its history shows deep, long losses. In the 2020 COVID crash it fell 26.9% and recovered in about a month. In the 2022 bear market it fell 42.5% and took about 51 months, until September 29, 2026, to win that back. Its deepest drop, 68.3% from September 2021 to October 2023, had still not been fully recovered as of October 27, 2026. Someone forced to sell in 2022 would have locked in large losses. The fund launched in 2019, so it has no 2008 record.

Income is small. The trailing yield was 0.69% as of October 27, 2026, paid twice a year. The fund costs 0.47% a year, which is $48 in the first year and $591 over 10 years in the SEC's $10,000 example. Past results don't predict future returns, and a plan should look at the whole portfolio, not one fund.

Matched by closest holdings overlap from the latest N-PORT reports (no similar fund shares 20% or more of its holdings).